SK Chemicals Co Ltd 2016 SR
The report highlights SK Chemicals' 2016 performance in Green Chemicals and Life Science businesses, achieving an earnings turnaround with KRW 1.15 trillion in sales. Key achievements include launching the world's first quadrivalent cell-culture influenza vaccine and acquiring FDA approval for the hemophilia treatment AFSTYLA. The company focused on eco-friendly materials like PETG and biodiesel, while reducing greenhouse gas emissions by 29.8% compared to BAU. It also emphasizes corporate governance, ethical management, and social contribution through programs like Hope Maker.
Company: SK Chemicals Co Ltd
Sector: Manufacturing
Country: South Korea
Year: 2016
Type: SR
Pages: 38
Back to company
SK Chemicals Co Ltd
Sustainability Report
The report highlights SK Chemicals' 2016 performance in Green Chemicals and Life Science businesses, achieving an earnings turnaround with KRW 1.15 trillion in sales. Key achievements include launching the world's first quadrivalent cell-culture influenza vaccine and acquiring FDA approval for the hemophilia treatment AFSTYLA. The company focused on eco-friendly materials like PETG and biodiesel, while reducing greenhouse gas emissions by 29.8% compared to BAU. It also emphasizes corporate governance, ethical management, and social contribution through programs like Hope Maker.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2016
Reporting Period
Jan 1, 2016 - Dec 31, 2016
Fiscal Year
2016
Published
Jun 1, 2017
Type
Sustainability Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
Other Standards
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Total Waste
Women on Board
Workplace Fatalities
Employees